Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | CTSK | P43235 | 13/20 | 0.45 |
| ▸ | CTSS | P25774 | 12/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30449614 | 1.00 | KCNH2 (0.46) | KCNH2CTSKCTSSKDM4EHSD17B10 | |
| SCHEMBL26538143 | 0.89 | KCNH2 (0.56) | KCNH2CTSKCTSS | |
| SCHEMBL9440177 | 0.86 | KCNH2 (0.68) | KCNH2HSD17B10 | |
| SCHEMBL17858980 | 0.84 | KCNH2 (0.36) | KCNH2CTSKCTSS | |
| SCHEMBL2954219 | 0.84 | HSD11B1 (0.41) | KCNH2CTSKCTSS | |
| SCHEMBL14732983 | 0.84 | KCNH2 (0.44) | KCNH2CTSKCTSS | |
| SCHEMBL22120171 | 0.82 | KCNH2 (0.52) | KCNH2CTSKCTSS | |
| SCHEMBL22931755 | 0.81 | SOS2 (0.37) | KCNH2CTSKCTSS | |
| SCHEMBL21199960 | 0.81 | HSD11B1 (0.44) | KCNH2CTSKCTSS | |
| SCHEMBL2953989 | 0.81 | MEN1 (0.44) | KCNH2CTSKCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160362421-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD SCIENCES, INC. | 2016-12-15 | — | — | US | disclosed |
| US-9115096-B2 | Fused heterocyclic compounds as ion channel modulators | GILEAD SCIENCES, INC. (US) | 2015-08-25 | — | — | US | disclosed |
| US-20120289493-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD SCIENCES, INC. | 2012-11-15 | — | — | US | disclosed |
| EP-1397364-B1 | NOVEL PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | LILLY CO ELI (US) | 2007-07-25 | — | — | EP | disclosed |
| US-7087626-B2 | Pyrrole derivatives as pharmaceutical agents | ELI LILLY AND COMPANY (US) | 2006-08-08 | — | — | US | disclosed |
| US-20040106604-A1 | Novel pyrrole derivatives as pharmaceutical agents | ELI LILLY AND COMPANY | 2004-06-03 | — | — | US | disclosed |
| EP-1397364-A1 | NOVEL PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | ELI LILLY AND COMPANY (US) | 2004-03-17 | — | — | EP | disclosed |
| WO-2002094833-A1 | NOVEL PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | ELI LILLY AND COMPANY (US) | 2002-11-28 | — | — | WO | disclosed |
| EP-0234104-B1 | NOVEL PYRIDINYLPYRIMIDINE DERIVATIVES, METHOD FOR PRODUCTION THEREOF AND A PLANT DISEASE PROTECTANT CONTAINING THEM AS THE ACTIVE INGREDIENT | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1990-10-24 | — | — | EP | disclosed |
| US-4868178-A | FUNGICIDE | SUMITOMO CHEMICAL COMPANY, LTD. (JP) | 1989-09-19 | — | — | US | disclosed |
| EP-0278610-A2 | Novel pyridinyl-s-triazine derivatives, method for production thereof and a fungicide containing them as the active ingredient | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1988-08-17 | — | — | EP | disclosed |
| US-4752608-A | Fungicidal pyridinylpyrimidine derivatives | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1988-06-21 | — | — | US | disclosed |
| EP-0234104-A2 | Novel pyridinylpyrimidine derivatives, method for production thereof and a plant disease protectant containing them as the active ingredient | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1987-09-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120289493-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | KCNJ2, CACNA1A, KCNH2 | KCNH2 3/4885CTSK 4310/4885CTSS 4499/4885 |
| US-20160362421-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | KCNJ2, CACNA1A, KCNH2 | KCNH2 3/4885CTSK 4310/4885CTSS 4499/4885 |
| US-20040106604-A1 | Novel pyrrole derivatives as pharmaceutical agents | TGFBR1, SMAD3, TGFBR2 | KCNH2 4570/4885CTSK 1815/4885CTSS 2048/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.